<DOC>
	<DOCNO>NCT01183494</DOCNO>
	<brief_summary>This study do determine maximum dose certain chemotherapy drug ( irinotecan ) tolerate part combination drug . There combination chemotherapy drug typically use treat cancer colon rectum : 5-Flurouracil ( 5-FU ) , leucovorin , irinotecan ; combination know FOLFIRI . At present time , Food Drug Administration ( FDA ) approve drug combination treatment cancer colon rectum . The FDA also approve use drug call bevacizumab ( Avastin ) combination FOLFIRI , consider one standard care patient colon rectal cancer spread . The best dose irinotecan use combination FOLFIRI bevacizumab know . Earlier study show high dos irinotecan use safely part FOLFIRI combination , unclear whether dos safe bevacizumab add combination .</brief_summary>
	<brief_title>A Genotype-guided Study Irinotecan Administered Combination With 5-fluorouracil/Leucovorin ( FOLFIRI ) Bevacizumab Advanced Colorectal Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis metastatic colorectal adenocarcinoma 2 . No prior chemotherapy metastatic disease 3 . Age ≥18 year 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ( 5 . Life expectancy &gt; 3 month 5 . Adequate organ function , include bone marrow ( absolute neutrophil count ( ANC ) ≥l500/μl , haemoglobin ≥ 9g/dL , platelet ≥ 100,000/ μl ) ; hepatic ( total bilirubin &lt; 1.6 mg/dl ; SGOT SGPT &lt; 2.5 x upper limit normal patient without liver metastasis &lt; 5x upper limit normal patient liver metastasis ) ; renal ( serum creatinine ≤ 1.5x upper limit normal ) . 6 . Patients eligible registered study , base upon criterion , genotyped UGT1A1*28 polymorphism stratify two group base presence UGT1A1*1/*1 UGT1A1*1/*28 genotype . 7 . Patients UGT1A1*28/*28 genotype carrier allele ( TA5 TA8 ) exclude . 8 . For patient evaluable response ( secondary end point ) , must least one measurable lesion define RECIST ( i.e. , lesion accurately measure least one dimension long diameter ≥ 20 mm use conventional technique ≥ 10 mm use spiral CT scan ) . 9 . Patients without measurable lesion include evaluated toxicity . 10 . Signed informed consent local IRB approval require . 11 . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation , 30 day final study treatment . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 1 . Prior irinotecan bevacizumab treatment 2 . Inflammatory bowel disease ( Crohn 's disease , ulcerative colitis ) 3 . Diarrhea great grade 1 4 . Bowel obstruction 5 . Documented brain metastasis 6 . Serious active infectious disease 7 . Active uncontrolled bleed fistulas 8 . Pregnancy 9 . Radiotherapy major surgery within 4 week 10 . Previous concurrent malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree five year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>